
Opinion|Videos|October 24, 2024
Osimertinib: Evolution of Treatment from Refractory Disease to Prevention of Drivers of Disease Progression
Author(s)Hatim Husain, MD
Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Agents such as osimertinib that first targeted resistance mechanisms in refractory disease are now being used to prevent drivers of disease progression.
- Please discuss your thoughts about this strategy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
3
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5




















